IL1A and cardiac hypertrophy: Cardiac-specific overexpression of human interleukin 1α (IL-1α) results in cardiac hypertrophy, and systemic administration of IL-1β antibodies or IL-1β deletion prevents aortic banding-induced hypertensive cardiac hypertrophy [27–29].